Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2023; 11(33): 7972-7979
Published online Nov 26, 2023. doi: 10.12998/wjcc.v11.i33.7972
Influence of ganglioside combined with methylprednisolone sodium succinate on efficacy and neurological function in patients with acute myelitis
Yu-Fei Sun, Li-Li Liu, Sha-Sha Jiang, Xian-Juan Zhang, Feng-Jun Liu, Wan-Ming Zhang
Yu-Fei Sun, Wan-Ming Zhang, Department of Special Medicine, Basic Medical College of Qingdao University, Qingdao 266071, Shandong Province, China
Li-Li Liu, Sha-Sha Jiang, Department of Medical Microbiology, Basic Medical College of Qingdao University, Qingdao 266075, Shandong Province, China
Xian-Juan Zhang, Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Feng-Jun Liu, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao 266000, Shandong Province, China
Co-first authors: Yu-Fei Sun and Li-Li Liu.
Author contributions: Sun YF and Liu LL contributed equally to this work and are co-first authors. Sun YF and Liu LL designed the research and wrote the first manuscript; Sun YF, Liu LL, Jiang SS, Zhang XJ, Liu FJ, and Zhang WM contributed to conceiving the research and analyzing data; Sun YF, Liu LL, and Zhang WM conducted the analysis and provided guidance for the research; and all authors reviewed and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethic Committee of Basic Medical College of Qingdao University (Approval No. QDWMkj-2020-012).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wan-Ming Zhang, MD, Doctor, Department of Special Medicine, Basic Medical College of Qingdao University, No. 821 Ningde Road, Qingdao 266071, Shandong Province, China. zhangwanming0532@126.com
Received: September 13, 2023
Peer-review started: September 13, 2023
First decision: September 28, 2023
Revised: October 11, 2023
Accepted: October 30, 2023
Article in press: October 30, 2023
Published online: November 26, 2023
Processing time: 72 Days and 0.8 Hours
ARTICLE HIGHLIGHTS
Research background

Acute myelitis (AM) can cause sudden sensory, motor and autonomic nervous dysfunction in patients, which negatively affects their daily activities and quality of life. Therefore, it is necessary to optimize exploration from a therapeutic perspective to curb the progression of the disease.

Research motivation

It is necessary to optimize the therapeutic strategy to improve the clinical outcomes of AM patients.

Research objectives

In this research, the effect of ganglioside (GM) combined with methylprednisolone sodium succinate (MPSS) on the curative effect and neurological function of patients with AM was investigated.

Research methods

Of the 108 AM patients selected, 52 cases were treated with gamma globulin plus MPSS (control group) and 56 cases were treated with GM plus MPSS (observation group). The two groups were then comparatively analyzed from the following perspectives: Efficacy, neurological function (sensory and motor function scores), occurrence of adverse events, recovery (time to sphincter function recovery, limb muscle strength recovery above grade 2, and ambulation), and inflammatory factors [interleukin-6 (IL-6); C-reactive protein (CRP); tumor necrosis factor-α (TNF-α)].

Research results

The treatment efficacy and sensory and motor function scores of the observation group were significantly higher than those of the control group, while the total incidence of adverse events such as rash, gastrointestinal discomfort, dyslipidemia and osteoporosis, as well as recovery indexes such as the time to sphincter function recovery, limb muscle strength recovery above grade 2, and ambulation was significantly lower. In addition, IL-6, CRP, and TNF-α levels reduced markedly in the observation group after treatment, significantly lower than the baseline and those of the control group.

Research conclusions

GM combined with MPSS shows significant advantages in enhancing efficacy and nerve function in patients with AM, accelerating recovery, inhibiting serum inflammation, and improving safety.

Research perspectives

Our findings may provide new insights and clinical references for the management and treatment of patients with AM.